Seqirus, Inc.
Global influenza vaccine developer and manufacturer operating industrial-scale production sites in the United States, United Kingdom and Australia. The organization operates both cell-culture and egg-based production platforms, develops adjuvanted and next-generation vaccine candidates (including self-amplifying mRNA), partners with governments for pandemic preparedness, and maintains clinical, regulatory and commercial capabilities to supply seasonal and pre-pandemic influenza vaccines.
Industries
N/A
Nr. of Employees
medium (51-250)
Seqirus, Inc.
Medical Information Portal: https://medinfo.seqirus.com/ (Hours: 8:00am to 5:00pm CST)
Products
Egg-based inactivated influenza vaccine (standard-dose, intramuscular)
Egg-propagated inactivated influenza vaccine formulations intended for active immunization against seasonal influenza in eligible age groups.
Adjuvanted inactivated influenza vaccine (for older adults)
Adjuvanted seasonal influenza vaccine formulation authorized for use in older adults to enhance immune response.
Cell-culture derived inactivated influenza vaccine
Inactivated influenza vaccine produced using cell-culture manufacturing, intended to reduce egg-adaptation and better match selected strains.
Egg-based inactivated influenza vaccine (standard-dose, intramuscular)
Egg-propagated inactivated influenza vaccine formulations intended for active immunization against seasonal influenza in eligible age groups.
Adjuvanted inactivated influenza vaccine (for older adults)
Adjuvanted seasonal influenza vaccine formulation authorized for use in older adults to enhance immune response.
Cell-culture derived inactivated influenza vaccine
Inactivated influenza vaccine produced using cell-culture manufacturing, intended to reduce egg-adaptation and better match selected strains.
Services
Manufacture and supply of pre-pandemic and pandemic influenza vaccine antigens and adjuvant reserves, and contractual delivery of reserved doses to government programs with surge and fill-and-finish capability.
Strategic licensing, in-licensing and collaborative arrangements to access external vaccine technologies and commercialize or distribute partnered products in defined markets.
Support for external investigator-initiated research, medical information services for healthcare professionals and operational adverse-event reporting channels.
Manufacture and supply of pre-pandemic and pandemic influenza vaccine antigens and adjuvant reserves, and contractual delivery of reserved doses to government programs with surge and fill-and-finish capability.
Strategic licensing, in-licensing and collaborative arrangements to access external vaccine technologies and commercialize or distribute partnered products in defined markets.
Support for external investigator-initiated research, medical information services for healthcare professionals and operational adverse-event reporting channels.
Expertise Areas
- Influenza vaccine development
- Pandemic preparedness and surge manufacturing
- Cell-culture vaccine production
- Egg-based vaccine production
Key Technologies
- Cell-culture vaccine production
- Egg-based vaccine production
- Oil-in-water adjuvant formulation
- Self-amplifying mRNA platforms
News & Updates
Company announced commencement of shipping its differentiated influenza vaccine portfolio to healthcare providers in preparation for the 2025/26 U.S. season.
Award to complete fill and finish for additional pre-pandemic vaccines and expand adjuvant reserves in support of U.S. pandemic preparedness.
Released results from RWE studies and a published study suggesting higher relative effectiveness of cell-based quadrivalent influenza vaccine versus egg-based formulations across several seasons.
Announcement of positive preclinical data supporting sa-mRNA influenza vaccine candidates in a peer-reviewed methods and development journal.
Company announced commencement of shipping its differentiated influenza vaccine portfolio to healthcare providers in preparation for the 2025/26 U.S. season.
Award to complete fill and finish for additional pre-pandemic vaccines and expand adjuvant reserves in support of U.S. pandemic preparedness.
Released results from RWE studies and a published study suggesting higher relative effectiveness of cell-based quadrivalent influenza vaccine versus egg-based formulations across several seasons.
Announcement of positive preclinical data supporting sa-mRNA influenza vaccine candidates in a peer-reviewed methods and development journal.